A new start-up has been launched with a dazzling, technology-enabled vision of putting genomics into the hands of the DNA’s owners – individuals – rather than what it calls genomics ‘middle men’.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
